Merrimack Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Merrimack Pharma (MACK) Misses Q2 EPS by 5c
August 7, 2018 6:37 AM EDTMerrimack Pharma (NASDAQ: MACK) reported Q2 EPS of ($1.33), $0.05 worse than the analyst estimate of ($1.28).
"A cornerstone of Merrimack\'s approach to drug development is our commitment to test targeted therapies in biomarker-enriched patient populations, resulting in smaller, shorter and more personalized studies that... More
